SCHEMBL23509

SCHEMBL23509

COc1cccc(C(=O)OOC(=O)c2cccc(OC)c2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.71
CES1 P23141 1/20 0.71
PARP1 P09874 1/20 0.67
ESR1 P03372 1/20 0.65
ESR2 Q92731 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.59
TP53 P04637 2/20 0.59
NPC1 O15118 5/20 0.59
RAB9A P51151 4/20 0.59
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
PRSS1 P07477 1/20 0.56
PRSS2 P07478 1/20 0.56
PRSS3 P35030 1/20 0.56
ABCG2 Q9UNQ0 1/20 0.56
ALDH1A1 P00352 1/20 0.55
PKM P14618 1/20 0.55
HPGD P15428 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP3 P42574 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7652880 0.94 CES2 (0.65) CES2CES1PARP1ESR1ESR2
SCHEMBL7627551 0.93 CES2 (0.62) CES2CES1PARP1ESR1ESR2
SCHEMBL7625784 0.89 CES2 (0.62) CES2CES1PARP1ESR1ESR2
SCHEMBL30393680 0.88 CES2 (0.71) CES2CES1PARP1ESR1ESR2
SCHEMBL447346 0.88 CES2 (0.71) CES2CES1PARP1ESR1ESR2
Methyl 3-Methoxybenzoate SCHEMBL29702092 0.88 SMN1; SMN2 (0.73) CES2CES1PARP1ESR1ESR2
Methyl 3-Methoxybenzoate SCHEMBL384913 0.88 SMN1; SMN2 (0.73) CES2CES1PARP1ESR1ESR2
SCHEMBL7630344 0.87 CES2 (0.56) CES2CES1PARP1ESR1ESR2
SCHEMBL7632759 0.87 CES2 (0.56) CES2CES1PARP1ESR1ESR2
SCHEMBL1356540 0.86 PARP1 (0.70) CES2CES1PARP1ESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3253561-B1 PROCESS FOR PRODUCING MODIFIED OLEFIN POLYMER IN AN EXTRUDER BOREALIS AG (AT) 2019-05-08 EP claimed
US-10105908-B2 Process for producing modified olefin polymer in an extruder BOREALIS AG (AT) 2018-10-23 US claimed
US-20170361543-A1 Process for Producing Modified Olefin Polymer in an Extruder BOREALIS AG (AT) 2017-12-21 US claimed
WO-2016124617-A1 PROCESS FOR PRODUCING MODIFIED OLEFIN POLYMER IN AN EXTRUDER BOREALIS AG (AT) 2016-08-11 WO claimed
US-12605917-B2 Multilayer sheet comprising a foamed layer suitable for food packaging BOREALIS AG (AT) 2026-04-21 US disclosed
EP-4667512-A1 INCREASED AREA STRETCH RATIO FOR CAPACITOR FILMS MADE OF A BIAXIALLY ORIENTED POLYPROPYLENE FILM Borealis GmbH (AT) 2025-12-24 EP disclosed
US-20240360303-A1 Method of Preparing Modified Propylene-Based Polymer and Modified Propylene-Based Polymer Prepared Thereby SK INNOVATION CO., LTD. (KR) 2024-10-31 US disclosed
CN-118834330-A Method for preparing modified propylene-based polymer and modified propylene-based polymer prepared by method SK新技术株式会社 2024-10-25 CN disclosed
US-20240247140-A1 FLAME RETARDANT COMPOSITION COMPRISING A HIGH MELT STRENGTH POLYPROPYLENE BOREALIS AG (AT) 2024-07-25 US disclosed
WO-2024141547-A1 PROPYLENE COMPOSITION BOREALIS AG (AT) 2024-07-04 WO disclosed
EP-4086299-B1 THERMALLY TREATED BIAXIALLY ORIENTED POLYPROPYLENE FILM BOREALIS AG (AT) 2024-07-03 EP disclosed
EP-4393969-A1 PROPYLENE COMPOSITION Borealis AG (AT) 2024-07-03 EP disclosed
US-6204348-B1 REACTING A POLYPROPYLENE WITH ETHYLENICALLY UNSATURATED MONOMER BOREALIS GMBH (AT) 2001-03-20 US disclosed
US-6136926-A CURING WITH ETHYLENICALLY UNSATURATED ORGANOSILANE COMPOUND; HEATING BELOW SOFTENING POINT BOREALIS GMBH (AT) 2000-10-24 US disclosed
US-5962594-A Segmented polyolefins BOREALIS AG (AT) 1999-10-05 US disclosed
US-5929127-A Fine-celled polyolefin foam materials BOREALIS AG (AT) 1999-07-27 US disclosed
EP-0910351-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-28 EP disclosed
EP-0907666-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. Searle & Co. (US) 1999-04-14 EP disclosed
WO-1997049736-A2 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed
WO-1997049387-A1 PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS G.D. SEARLE AND CO. (US) 1997-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605917-B2 Multilayer sheet comprising a foamed layer suitable for food packaging PTGER3, MFAP1, TAS2R13 CES2 4836/4885CES1 4802/4885PARP1 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.